1. Labarre, J . Sur Les Possibilites d’un Traitement Du Diabete par I’incretine. 1932.
Google Scholar2. Nauck, MA, Kleine, N, Orskov, C, Holst, JJ, Willms, B, Creutzfeldt, W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-744.
Google Scholar | Crossref | Medline | ISI3. Näslund, E, Bogefors, J, Skogar, S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol. 1999;277:R910-R916.
Google Scholar | Medline4. Shah, M, Vella, A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15:181-187.
Google Scholar | Crossref | Medline5. Davies, MJ, D’Alessio, DA, Fradkin, J, et al. Correction to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the american Diabetes association (ADA) and the european association for the study of Diabetes (EASD). Diabetologia. 2019;62:873-2498.
Google Scholar | Crossref | Medline6. American Diabetes Association. 9 . Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S90-S102.
Google Scholar7. American Diabetes Association. 2 . Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S13-S28.
Google Scholar | Crossref | Medline8. American Diabetes Association. 1 . Improving care and promoting health in populations: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S7-S12.
Google Scholar9. American Diabetes Association. 10 . Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103-S123.
Google Scholar10. Filippatos, TD, Panagiotopoulou, TV, Elisaf, MS. Adverse effects of GLP-1 receptor agonists. Rev Diabetic Stud 2014;11:202-230.
Google Scholar | Crossref | Medline11. Edwards, CM, Todd, JF, Ghatei, MA, Bloom, SR. Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin Sci. 1998;95:719-724.
Google Scholar | Crossref | Medline | ISI12. Lerche, S, Soendergaard, L, Rungby, J, et al. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. Clin Endocrinol. 2009;71:500-506.
Google Scholar | Crossref | Medline13. Seaquist, ER, Anderson, J, Childs, B, et al. Hypoglycemia and Diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384-1395.
Google Scholar | Crossref | Medline | ISI14. Nauck, M, Frid, A, Hermansen, K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
Google Scholar | Crossref | Medline | ISI15. Marre, M, Shaw, J, Brändle, M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Med. 2009;26:268-278.
Google Scholar | Crossref | Medline | ISI16. Nauck, MA, Heimesaat, MM, Behle, K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239-1246.
Google Scholar | Crossref | Medline | ISI17. Gough, SC, Bode, B, Woo, V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885-893.
Google Scholar | Medline | ISI18. Wysham, C, Bonadonna, RC, Aroda, VR, et al. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. Diabetes Obes Metab. 2017;19:1408-1415.
Google Scholar | Medline19. Vilsbøll, T, Krarup, T, Madsbad, S, Holst, JJ. No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabetic Med. 2001;18:144-149.
Google Scholar | Crossref | Medline | ISI20. Buse, JB, Rosenstock, J, Sesti, G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
Google Scholar | Crossref | Medline | ISI21. Knop, FK, Vilsbøll, T, Larsen, S, Madsbad, S, Holst, JJ, Krarup, T. No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis. Diabetes Care. 2003;26:2581-2587.
Google Scholar | Crossref | Medline22. Miholic, J, Orskov, C, Holst, JJ, Kotzerke, J, Meyer, HJ. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci. 1991;36:1361-1370.
Google Scholar | Crossref | Medline23. Blevins, T, Pullman, J, Malloy, J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301-1310.
Google Scholar | Crossref | Medline | ISI24. Ratner, RE, Rosenstock, J, Boka, G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabetic Med. 2010;27:1024-1032.
Google Scholar | Crossref | Medline | ISI25. Park, MK . Glucagon-Like peptide-1. Handb Horm. 2016;135:e17C-5.
Google Scholar26. Fehmann, H-C, Göke, R, Göke, B. Glucagon-like peptide-1(7-37)/(7-36)amide is a new incretin. Mol Cell Endocrinol. 1992;85:C39-C44.
Google Scholar | Crossref | Medline27. Holst, JJ . The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439.
Google Scholar | Crossref | Medline | ISI28. Leech, CA, Dzhura, I, Chepurny, OG, et al. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Prog Biophys Mol Biol. 2011;107:236-247.
Google Scholar | Crossref | Medline29. Chen, Q, Miller, LJ, Dong, M. Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor. Am J Physiol. 2010;299:E62-E68.
Google Scholar30. Drucker, DJ, Philippe, J, Mojsov, S, Chick, WL, Habener, JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci. 1987;84:3434-3438.
Google Scholar | Crossref | Medline | ISI31. Elrick, H, Stimmler, L, Hlad, CJ, Arai, Y. Plasma insulin response to oral and intravenous glucose administration1. J Clin Endocrinol Metab. 1964;24:1076-1082.
Google Scholar | Crossref | Medline | ISI32. Holst, JJ . Long-acting glucagon-like peptide-1 receptor agonist-status December 2018. Ann Transl Med. 2019;7:83.
Google Scholar | Crossref | Medline33. Das, A, Geetha, KM, Hazarika, I. Contemporary updates on the physiology of glucagon like peptide-1 and its agonist to treat type 2 Diabetes mellitus. Int J Pept Res Ther. 2020;26:1211-1221.
Google Scholar | Crossref34. Brunton, S . GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68:557-567.
Google Scholar | Crossref | Medline | ISI35. Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2016;375:311-322.
Google Scholar | Crossref | Medline | ISI36. Gerstein, HC, Colhoun, HM, Dagenais, GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-130.
Google Scholar | Crossref | Medline37. Elashoff, M, Matveyenko, AV, Gier, B, Elashoff, R, Butler, PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-156.
Google Scholar | Crossref | Medline | ISI38. Gotfredsen, CF, Mølck, A-M, Thorup, I, et al. The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. Diabetes. 2014;63:2486-2497.
Google Scholar | Crossref | Medline | ISI39. Cao, C, Yang, S, Zhou, Z. GLP-1 Receptor Agonists and Pancreatic Safety Concerns in Type 2 Diabetic Patients: Data From Cardiovascular Outcome Trials. Springer; 2020.
Google Scholar40. Fusco, J, Xiao, X, Prasadan, K, et al. GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor. Sci Rep. 2017;7:9100-9106.
Google Scholar | Crossref | Medline41. Irons, B, Minze, M. Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes Metab Syndr Obes. 2014;7:15.
Google Scholar | Crossref | Medline42. Onoviran, OF, Li, D, Toombs Smith, S, Raji, MA. Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. Ther Adv Chronic Dis. 2019;10:2040622319862691.
Google Scholar | SAGE Journals | ISI43. de Heer, J, Holst, JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes. 2007;56:438-443.
Google Scholar | Crossref | Medline44. Ruby, RJ, Armato, JP, Pyke, C, Peters, AL. GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma. Diabetes Care. 2014;37:e177-e178.
Google Scholar | Crossref | Medline45. Palladino, AA, Sayed, S, Levitt Katz, LE, Gallagher, PR, De León, DD. Increased glucagon-like peptide-1 secretion and postprandial hypoglycemia in children after Nissen fundoplication. J Clin Endocrinol Metab. 2008;94:39-44.
Google Scholar | Crossref | Medline46. Huthmacher, JA, Meier, JJ, Nauck, MA. Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis. Diabetes Care. 2020;43:2303-2312.
Google Scholar | Crossref | Medline47. Rehfeld, JF . The origin and understanding of the incretin concept. Front Endocrinol. 2018;9:387.
Google Scholar | Crossref | Medline48. Madsbad, S . Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18:317-332.
Google Scholar | Crossref | Medline | ISI49. Sun, F, Yu, K, Yang, Z, et al. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res. 2012;2012:230624.
Google Scholar | Crossref |